Fosravuconazole

Fosravuconazole (BMS-379224), a proagent of Ravuconazole, is an orally active broad spectrum antifungal agent. Fosravuconazole can be used for candidiasis, onychomycosis and parasitemia research[1][2][3].

Product Specifications

CAS Number

[351227-64-0]

Product Name Alternative

BMS-379224; E-1224

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Fungal; Parasite

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Fosravuconazole.html

Purity

99.86

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

N#CC1=CC=C(C2=CSC([C@H](C)[C@@](OCOP(O)(O)=O)(C3=CC=C(F)C=C3F)CN4N=CN=C4)=N2)C=C1

Molecular Formula

C23H20F2N5O5PS

Molecular Weight

547.47

Precautions

H302, H315, H319

References & Citations

[1]Shinichi Watanabe, et al. Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study. J Dermatol. 2018 Oct;45 (10) :1151-1159.|[2]Katsura Hata, et al. Development of E1224 by leveraging a strategic partnership for the medicines creation against neglected tropical diseases. Parasitol Int. 2020 Dec 25;81:102278.|[3]Lívia de Figueiredo Diniz, et al. Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice. Antimicrob Agents Chemother. 2018 May 25;62 (6) :e00401-18.